Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

LDCT screening reduces lung cancer mortality in high-risk adults. Eligibility commonly includes age beginning at 50 and a ≥20 pack-year history who currently smoke or quit within the past 15 years. This patient qualifies. Screening is annual while criteria remain met and the individual is healthy enough to undergo curative therapy if a cancer is found. Chest X-ray and sputum cytology (Option A) have not shown mortality benefit. A single baseline CT (Option C) misses interval cancers; benefits accrue with repeated annual scans. Dismissing screening due to age <55 (Option D) reflects outdated thresholds. Shared decision-making should include benefits, false positives, incidental findings, radiation exposure, and the critical role of smoking cessation—the most effective cancer prevention strategy. The APRN coordinates referral to an accredited LDCT program, ensures standardized nodule management (Lung-RADS), addresses comorbidities that influence surgical candidacy, and provides cessation pharmacotherapy and counseling, documenting the plan and recall schedule in the EHR.